BioSpace News Archive

Drug Development

Exceeding Expectations, ImmunoGen Eyes 2022 Approval for Ovarian Cancer Drug Mirvetuximab Soravtansine

ImmunoGen shares positive results from its Phase III SORAYA trial, which is evaluating the use of mirvetuximab soravtansine for treating ovarian cancer.

December 1, 2021
·
2 min read
·
Vanessa Doctor, RN
Policy

Merck’s Molnupiravir Narrowly Nets FDA Panel Blessing

The FDA’s Antimicrobial Drugs Advisory Committee voted 13 to 10 to recommend emergency authorization of molnupiravir. Read more about the authorization here.

December 1, 2021
·
2 min read
·
Alex Keown
Drug Development

COVID-19 Update: Omicron Threat Remains Unknown and Breakthrough Factors

It may take two to four weeks before experts have enough data to know whether Omicron is a bigger threat than Delta. Much of what is known is based on lab tests and models of the virus’ spike protein mutations.

December 1, 2021
·
5 min read
·
Mark Terry
Deals

Sanofi Steps Up Vaccine Game with Origimm Acquisition

The takeover is part of the French biotech giant’s “Play to Win” strategy of growing its global vaccines pipeline through the acquisition of promising projects and companies.

December 1, 2021
·
2 min read
·
Vanessa Doctor, RN
Deals

23andMe Ramping Up Drug Development Efforts with Key Moves

23andMe raised $592 million in proceeds from the IPO and, as of September 30, had about $700 million. With that cash in hand, it plans to push faster and deeper into drug development.

December 1, 2021
·
2 min read
·
Mark Terry
Business

One-Year Data Will Support NDA for Biogen/Sage MDD Drug

The 12-month data showed that 50 mg of zuranolone was well-tolerated among adults with MDD.

December 1, 2021
·
3 min read
·
Alex Keown
Business

Curie Therapeutics Forms to Seize the Potential of Radiopharmaceuticals

The radiopharmaceuticals being developed by Curie are composed of rationally designed conjugates in contrast to delicately chosen biological targets.

December 1, 2021
·
2 min read
·
Rosey Alba
Drug Development

Biopharma is Tackling Misfolding Proteins in Parkinson’s Disease

Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.

December 1, 2021
·
7 min read
·
BioSpace Editorial Staff
10 Ways to Combat Workplace Stress

Are you looking for effective ways to combat workplace stress? Here are 10 ways that can help you improve and increase the productivity of your day at work.

December 1, 2021
·
8 min read
·
Alina Zahid
Drug Development

Vertex Kidney Disease Drug Proves its Worth in Phase II

The company plans to move it into Phase III studies in APOL1-mediated kidney disease, including FSGS, in the first quarter of 2022.

December 1, 2021
·
3 min read
·
Mark Terry